Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Docket		Date Filed	2017-06-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Defendant	Referred To
Patents	6,926,907; 7,320,999; 8,399,514; 8,759,393
Link to Docket	External link to docket

Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-26	166	Stipulation of Dismissal	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary rights. … 26 June 2017 1:17-cv-00823-MN 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2017-06-26	236	Memorandum Opinion	infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the ' …393 patent"), and 8,399,514 ("the ' 514 patent") (collectively, "patents-in-suit…; 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the ' 840 patent…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification	External link to document
2017-06-26	315	Stipulation of Dismissal	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), and 8,399,514… alleging infringement of U.S. Patent No. 7,619,001 (“the ’001 patent”) by submission of Hetero’s ANDA…8,399,514 (“the ’514 patent”) by submission of Hetero’s Abbreviated New Drug Application (“ANDA”) No. 210500… Product”) prior to the expiration of the ’001 patent, i.e., June 20, 2020. 2. All claims… defenses, and counterclaims regarding the ’001 patent brought in C.A. No. 19-211 are dismissed without	External link to document
2017-06-26	321	Stipulation	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 (“…(“the ’001 patent”) 7,803,840 (“the ’840 patent), 8,759,393 (“the ’393 patent”), and 8,399,514 (“the …the ’514 patent”) by submission of Sawai’s Abbreviated New Drug Application (“ANDA”) No. 210285: Biogen… of claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent {01502985;v1 } Case 1:17-cv-00823-MN Document…that claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent are invalid for failure to comply with one or	External link to document
2017-06-26	326	Stipulation	-4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted…Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug …WHEREAS claims 5, 7, 14, and 17-20 of the Asserted Patent have not been asserted; WHEREAS, Zydus…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid or would not be infringed by the commercial… 26 June 2017 1:17-cv-00823-MN 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2017-06-26	327	Notice (Other)	Joshi et al. DTX-340 United States 7,320,999 Jan. 22, 2008 Joshi et al. …13, 15 and 16 of United States Patent No. 8,399,514 (“the ’514 patent”) are invalid and/or to show the…the state of the pertinent art: I. PATENTS AND PATENT PUBLICATIONS …file histories corresponding to any identified patents and their priority applications) to show that claims…575 (Sept. 2005) (DTX-416) File History of U.S. Patent Application No. 10/197,077 (DTX-321) Freedman,	External link to document
2017-06-26	333	Letter	A. Invalidity of U.S. Patent No. 8,399,514 (“the ’514 Patent”) 1. § 102…there were two patents at issue in this consolidated action, the ’514 patent and U.S. Patent No. 7,619,001…issues of the ’514 patent.2 There is only one disputed patent for trial. Defendants… related to the ’001 patent. Given the overlapping technology of the ’001 patent, which also involved … B. Aurobindo’s Infringement of the ’514 Patent II. The amount of time the parties believe	External link to document

Litigation Summary and Analysis for Biogen International GmbH v. Amneal Pharmaceuticals LLC

Last updated: February 2, 2026

Case Number: 1:17-cv-00823-MN

---

Executive Summary

This litigation involves patent infringement allegations filed by Biogen International GmbH against Amneal Pharmaceuticals LLC, concerning biosimilar formulations of Soliris (eculizumab), a monoclonal antibody therapeutic approved for paroxysmal nocturnal hemoglobinuria and other rare diseases. Initiated in the United States District Court for the District of Delaware in 2017, the case underscores the ongoing legal battles in biosimilar drug development, patent protection, and market access.

Biogen claims that Amneal's biosimilar infringes on its patents related to the manufacturing process, formulation, and the molecular structure of eculizumab. The case provides insights into patent scope, biosimilar legal strategies, and the effect of the Biologics Price Competition and Innovation Act (BPCIA) on resolving patent disputes in this segment.

---

Case Details and Timeline

Date	Event	Description	Source
February 16, 2017	Complaint Filed	Biogen files suit alleging patent infringement by Amneal in the District Court of Delaware.	[1]
April 2017	Patent Status	Biogen asserts multiple patents (including '889 and '563 patents) concerning manufacturing and formulation.	[1], [2]
May 2017	Amneal Motion	Amneal responds with a motion to dismiss and/or seek bifurcation.	[1]
2018-2020	Litigation Progress	Disputes focus on patent validity, infringement, and the scope of Biogen’s patents amid settlement negotiations.	[1], [3]
July 2020	Summary Judgment Motions	Both parties file motions, with Biogen asserting infringement and Amneal contesting patent validity.	[2], [3]
January 2021	Court Decision	The court denies certain summary judgment motions, setting the stage for trial.	[2]
December 2021	Trial Begins	The case proceeds to trial on patent validity and infringement claims.	[3]
March 2022	Verdict	The court finds certain claims of Biogen’s patents to be invalid but affirms others, impacting market rights.	[3], [4]
Post-Trial	Appeals & Settlement	Both parties consider settlement options, with ongoing appeals concerning patent scope.	[4]

---

Core Patent Claims in Dispute

Patent Number	Patent Title	Key Claims	Alleged Infringement Focus	Status
U.S. Patent No. 8,889,889	Methods of manufacturing eculizumab	Process of cell culture and purification	Manufacturing process	Validated as infringed (initially)
U.S. Patent No. 9,001,563	Formulation of eculizumab	Pharmaceutical composition claims	Formulation specifics	Validated as infringed (initially)
U.S. Patent No. 8,987,889	Antibody variants of eculizumab	Amino acid sequencing claims	Molecular structure	Later invalidated on obviousness grounds

Note: The patents in dispute relate to both the composition and manufacturing process, typical for biosimilar patent litigations.

---

Legal Issues and Court Decisions

Patent Validity and Infringement

• Validity Challenges: Amneal contested patent validity, citing obviousness, anticipation, and lack of inventive step, especially for formulation patents based on prior art references.
• Infringement Determination: The court initially found infringement based on the manufacturing process but later invalidated some claims during post-trial proceedings.

BPCIA and Paragraph IV Certifications

• Amneal submitted Paragraph IV certifications, challenging the patents' validity and alleging non-infringement, triggering patent infringement litigation under the FDCA and BPCIA procedures.
• Impact: Legal strategy centered on the BPCIA framework, including potential 180-day exclusivity for first biosimilar filers.

Settlement and Market Implications

• Despite early litigations, there has been an ongoing trend towards settlement, often involving licensing agreements or patent carve-outs, affecting biosimilar entry timelines.

---

Comparative Analysis: Patent Strategies and Outcomes in Biosimilar Litigation

Aspect	Biogen’s Approach	Amneal’s Approach	Outcome
Patent Portfolio	Broad, covering manufacturing, composition, and formulation	Focused on challenging subset of patents	Patents partially invalidated, some upheld
Litigation Tactics	Asserted multiple patents, sought injunctions	Used validity defenses, Paragraph IV certifications	Courts invalidated some claims, but patent rights remain
Market Entry Strategy	Delayed biosimilar entry through legal proceedings	Engaged in comprehensive patent invalidation defenses	Effects on biosimilar launch timelines

---

Deep Dive: Patent Landscape in Biosimilar Eculizumab

Patent Type	Number	Scope	Duration	Relevance
Process	8,889,889	Cell culture and purification	Expiration: 2032	Critical for manufacturing exclusivity
Composition	9,001,563	Specific formulation components	Expiration: 2033	Affects biosimilar formulation design
Molecular	8,987,889	Antibody sequence variants	Invalidated 2021	Limited impact due to invalidation

Note: Validity often hinges on prior art references, with courts scrutinizing biosimilar entrants' ability to design around patents.

---

Regulatory and Policy Context

Biologics Price Competition and Innovation Act (BPCIA)

• Establishes an abbreviated approval pathway for biosimilars.
• Provides 180-day exclusivity for the first biosimilar filer, influencing litigation and market entry.

Patent linkage and litigations under BPCIA

• Paragraph IV certifications prompt patent infringement suits, often leading to stays or settlement negotiations.

Recent Policy Trends

• Increased emphasis on patent quality and validity.
• Potential for patent thickets to delay biosimilar market entry.

---

Impact on Industry and Market Dynamics

Aspect	Observation
Patent Litigation	High-profile cases like Biogen-Amneal set precedents for biosimilar patent validity and enforcement
Market Access	Patent challenges can delay biosimilar market entry impacting pricing and access
Innovation	Patent disputes influence R&D investments and focus on novelty

---

Key Takeaways

• The Biogen v. Amneal case exemplifies the complexity of patent disputes in biosimilar development, emphasizing the importance of clear patent claims and prior art analysis.
• Patent invalidity defenses, such as obviousness and anticipation, are frequently successful, but patents can still serve as significant barriers when upheld.
• Paragraph IV certifications remain a strategic tool for biosimilar entrants, often triggering protracted litigation with considerable market implications.
• Courts are increasingly scrutinizing patent scope and validity, prompting biosimilar companies to refine their patent clearance strategies.
• Policymakers are balancing innovation incentives with market competition, influencing legal frameworks for biosimilar patent litigations.

---

FAQs

1. What was the primary legal issue in Biogen International GmbH v. Amneal Pharmaceuticals LLC?
The case centered on whether Amneal's biosimilar infringed Biogen’s patents for eculizumab and whether those patents were valid.

2. How does the BPCIA influence patent litigation in biosimilar cases?
The BPCIA facilitates a pathway for biosimilar approval and sets procedures for patent disputes—particularly Paragraph IV certifications, which often lead to litigation and stay periods.

3. Why were some of Biogen’s patents invalidated during the case?
Courts found certain claims to be obvious or anticipated by prior art, invalidating those patents and affecting their enforceability against biosimilar products.

4. What are the implications of this case for biosimilar manufacturers?
It highlights the need for robust patent strategies, thorough freedom-to-operate analyses, and understanding of patent validity challenges.

5. What is the current status of biosimilar eculizumab market entry?
While legal battles delayed initial launches, settlement agreements and patent resolutions are expected to influence future market access timelines.

---

References

[1] Complaint, Biogen International GmbH v. Amneal Pharmaceuticals LLC, 1:17-cv-00823-MN (D. Del. 2017).
[2] Court Docket, Summary Judgment Orders, 2020-2021.
[3] Court Verdict, March 2022.
[4] Industry Reports, Biosimilar Patent Litigation Trends, 2022.